NCT07257809

Herombopag Treated T-DM1 Induced Platelet Reduction

A Multicenter, Single-arm Exploratory Clinical Study Evaluating the Efficacy and Safety of T-DM1 in Patients With Breast Cancer Who Developed Thrombocytopenia.

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 56 (estimated)
• Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm study planned to enroll 56 breast cancer patients who experienced grade 2 or higher thrombocytopenia following prior chemotherapy and achieved normalization (platelet count ≥100 × 109/L and ≥200 × 109/L) through intervention.

Conditions

• Thrombocytopenia

Interventions

Type	Name	Description
DRUG	Herombopag Olamine Tablets	Herombopag 7.5 mg po qd，d1-14

Timeline

• Start date: 2025-10-13
• Primary completion: 2026-09-26
• Completion: 2027-09-26
• First posted: 2025-12-02
• Last updated: 2025-12-02

Locations

1 site across 1 country: China